Floatz Rating
B58/100
Confidence
Indicative
Sponsor
I-Mab Biopharma US Limited
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07432295CT.gov Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | — | Recruiting | — | — | — |
NCT07542262CT.gov Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers | — | Enrolling By Invitation | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05867121CT.gov A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 | — | Completed | — | — | — |
NCT04900818CT.gov Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT04396821CT.gov A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04208958CT.gov Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer | — | Completed | — | — | — |
NCT04180371CT.gov Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | — | Active Not Recruiting | — | — | — |
NCT04044859CT.gov ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | — | Active Not Recruiting | — | — | — |
Show 8 more trialsShow fewer
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03342417CT.gov Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | — | Terminated | — | — | — |
NCT03259867CT.gov Combination of TATE and PD-1 Inhibitor in Liver Cancer | — | Recruiting | — | — | — |
NCT02983045CT.gov A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | — | Completed | — | — | — |
NCT02572687CT.gov A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | I-Mab Biopharma US Limited | P2 | B · 58 |
| Rivoceranib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P4 | BBB |
| Fluorouracilum | I-Mab Biopharma US Limited | P4 | BB |
| Oxaliplatin | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Epirubicin | Rondo Therapeutics | P3 | BB |
| Irinotecan | Shenzhen Xinhe Biomedical | P4 | BB |
| Docetaxel | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
+42 more in the Gastric Cancer cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Gastric Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-gastric-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →